Enzymatic sialidases remove sialic acids before mass spectrometry, simplifying O-linked glycan analysis while preserving glycoprotein integrity.
Targeting different CD37 epitopes, these bispecific antibodies strengthen Fc-Fc interactions to improve CDC and ADCC against CD37-expressing cells.
DLL3-binding antibodies internalize in tumor cells, directing toxic payloads toward cancer while limiting harm to normal tissues.